Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide, accounting for approximately 18% of all cancer deaths.1 Despite treatment with platinum-based chemotherapy, the standard of care for first-line therapy, patients with metastatic NSCLC have a median survival of approximately 10 months, and a 5-year survival rate of less than 5%. Immunotherapeutic approaches have demonstrated clinical efficacy in several cancer types, including melanoma, hormone-refractory prostate cancer, and lung cancer.3,4.
A Collaboration of the San Antonio Bioscience and Medical Research Community
A first-of-its-kind initiative between public and private sector to catalog and highlight Bioscience research in the city of San Antonio and the surrounding areas.
Latest Projects
The University of Texas at San Antonio
The University of Texas at San Antonio
Southwest Research Institute
Southwest Research Institute
The University of Texas at San Antonio
The University of Texas at San Antonio